Tudor Investment Corp ET AL Invests $1.31 Million in Codexis, Inc. $CDXS

Tudor Investment Corp ET AL bought a new stake in Codexis, Inc. (NASDAQ:CDXS) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 537,833 shares of the biotechnology company’s stock, valued at approximately $1,312,000. Tudor Investment Corp ET AL owned about 0.60% of Codexis as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of CDXS. Opaleye Management Inc. raised its position in Codexis by 32.6% during the 2nd quarter. Opaleye Management Inc. now owns 12,600,000 shares of the biotechnology company’s stock worth $30,744,000 after buying an additional 3,100,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Codexis by 1.8% in the third quarter. Vanguard Group Inc. now owns 4,669,815 shares of the biotechnology company’s stock worth $11,394,000 after acquiring an additional 80,602 shares during the period. Millennium Management LLC increased its stake in shares of Codexis by 3,376.5% in the third quarter. Millennium Management LLC now owns 4,067,559 shares of the biotechnology company’s stock worth $9,925,000 after acquiring an additional 3,950,557 shares during the period. Nantahala Capital Management LLC raised its holdings in shares of Codexis by 42.4% during the second quarter. Nantahala Capital Management LLC now owns 4,030,619 shares of the biotechnology company’s stock worth $9,835,000 after purchasing an additional 1,200,000 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Codexis by 8.7% during the third quarter. Ameriprise Financial Inc. now owns 2,773,646 shares of the biotechnology company’s stock valued at $6,768,000 after purchasing an additional 222,840 shares during the period. Institutional investors and hedge funds own 78.54% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Stifel Nicolaus set a $5.00 price target on shares of Codexis in a report on Thursday, March 12th. Wall Street Zen raised Codexis from a “strong sell” rating to a “hold” rating in a report on Saturday, March 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Codexis in a report on Thursday, March 12th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Codexis in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Codexis currently has a consensus rating of “Hold” and a consensus price target of $5.00.

Codexis Price Performance

CDXS opened at $1.58 on Monday. The company has a fifty day moving average of $1.36 and a two-hundred day moving average of $1.81. The stock has a market capitalization of $143.57 million, a price-to-earnings ratio of -3.04 and a beta of 2.49. Codexis, Inc. has a fifty-two week low of $0.96 and a fifty-two week high of $3.87. The company has a debt-to-equity ratio of 0.79, a quick ratio of 3.75 and a current ratio of 3.82.

Codexis (NASDAQ:CDXS) last posted its earnings results on Wednesday, March 11th. The biotechnology company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.10. Codexis had a negative return on equity of 90.51% and a negative net margin of 62.47%.The firm had revenue of $38.92 million for the quarter, compared to analysts’ expectations of $35.83 million. On average, research analysts expect that Codexis, Inc. will post -0.77 earnings per share for the current year.

Codexis Profile

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.